This company has been marked as potentially delisted and may not be actively trading. Aquinox Pharmaceuticals (AQXP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AQXP vs. CALT, ZYME, CMRX, CDMO, SBTX, MENS, MBX, RVNC, CKPT, and AVTEShould you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), Silverback Therapeutics (SBTX), Jyong Biotech (MENS), MBX Biosciences (MBX), Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), and Aerovate Therapeutics (AVTE). Aquinox Pharmaceuticals vs. Its Competitors Calliditas Therapeutics AB (publ) Zymeworks Chimerix Avid Bioservices Silverback Therapeutics Jyong Biotech MBX Biosciences Revance Therapeutics Checkpoint Therapeutics Aerovate Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Aquinox Pharmaceuticals (NASDAQ:AQXP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Do insiders & institutionals have more ownership in CALT or AQXP? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 71.7% of Aquinox Pharmaceuticals shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 4.0% of Aquinox Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, CALT or AQXP? Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Aquinox Pharmaceuticals has a beta of -7.37, indicating that its stock price is 837% less volatile than the S&P 500. Is CALT or AQXP more profitable? Aquinox Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Aquinox Pharmaceuticals' return on equity of -30.13% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Aquinox Pharmaceuticals N/A -30.13%-28.08% Which has preferable valuation & earnings, CALT or AQXP? Aquinox Pharmaceuticals has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Aquinox Pharmaceuticals$25M20.02-$31.58MN/AN/A Does the media prefer CALT or AQXP? In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Aquinox Pharmaceuticals'average media sentiment score. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Aquinox Pharmaceuticals Neutral SummaryAquinox Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 6 of the 9 factors compared between the two stocks. Get Aquinox Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AQXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQXP vs. The Competition Export to ExcelMetricAquinox PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$500.46M$799.38M$5.57B$9.02BDividend YieldN/A4.84%5.25%4.03%P/E RatioN/A1.3027.1820.14Price / Sales20.02227.16417.49184.08Price / CashN/A23.4437.0657.97Price / Book6.886.178.085.60Net Income-$31.58M-$27.58M$3.16B$248.50M Aquinox Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQXPAquinox PharmaceuticalsN/A$21.26+4.8%N/A-47.0%$500.46M$25M0.008CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.1372 of 5 stars$12.50-0.4%$21.00+68.1%+45.1%$869.16M$93.38M-8.33460CMRXChimerix0.6386 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.8989 of 5 stars$12.50+0.1%$12.25-2.0%+64.8%$799.18M$139.91M-5.23320High Trading VolumeSBTXSilverback TherapeuticsN/A$18.20+0.7%N/A+73.7%$656.26MN/A-7.5283Gap UpHigh Trading VolumeMENSJyong BiotechN/A$8.41-1.1%N/AN/A$639.41MN/A0.0031Gap DownMBXMBX Biosciences2.55 of 5 stars$11.64+2.0%$37.50+222.2%N/A$389.06MN/A0.0036Positive NewsRVNCRevance Therapeutics2.7757 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500CKPTCheckpoint Therapeutics0.5333 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210AVTEAerovate TherapeuticsN/A$9.99+8.7%N/A-82.2%$289.56MN/A-3.3420Gap UpHigh Trading Volume Related Companies and Tools Related Companies CALT Competitors ZYME Competitors CMRX Competitors CDMO Competitors SBTX Competitors MENS Competitors MBX Competitors RVNC Competitors CKPT Competitors AVTE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AQXP) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
